10-K: Inhibitor Therapeutics Reports 2024 Annual Results, Focuses on Itraconazole Development for Cancer Therapies

Inhibitor Therapeutics' 2024 annual report highlights ongoing efforts to develop itraconazole-based therapies for various cancers, with a focus on regulatory pathways and strategic partnerships.

Summary

• Inhibitor Therapeutics, Inc. is a pharmaceutical development company focused on commercializing innovative therapeutics based on approved active pharmaceuticals for cancer and non-cancerous proliferation disorders.
• The company's primary focus is on developing therapies for BCCNS, prostate, and lung cancers using itraconazole.
• In December 2023, INTI entered an exclusive license agreement with Johns Hopkins University for worldwide patent rights related to the treatment of prostate cancer, BCC, and lung cancer.
• INTI is pursuing a pre-IND meeting with the FDA to discuss the development plan for itraconazole in treating BCC tumors in BCCNS patients.
• The company is collaborating with Avior Bio, Inc. to create a novel formulation of itraconazole, with results expected in the first half of 2025.
• INTI estimates a potential U.S. market opportunity for its anti-cancer therapies, including $215M for prostate cancer, $270M for lung cancer, and $900M for skin cancer at year 5.
• The company's strategy includes seeking FDA programs to expedite drug approvals, commercializing with exclusivity, forming a scientific advisory board, pursuing strategic partnerships, and exploring potential acquisitions.
• INTI reported research and development expenses of $1.7 million for 2024, compared to $1.4 million in 2023.
• General and administrative expenses were approximately $2.0 million for both 2024 and 2023.
• The company had approximately $5.6 million in cash on hand as of December 31, 2024.
• INTI believes its current cash is sufficient to execute its business plan without requiring additional clinical trials.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is making progress in its clinical development programs and has sufficient cash for its current plans, it is still in the early stages of development and faces significant risks and uncertainties. The company's history of net losses and the lack of an active trading market for its common stock also contribute to a neutral sentiment.

Positives

• The company has secured exclusive worldwide patent rights to a Granted US Patent, No. 8,980,930 entitled New Angiogenesis Inhibitors from Johns Hopkins University.
• INTI is actively pursuing a pre-IND meeting with the FDA to obtain feedback on its drug development and regulatory plan.
• The company is collaborating with Avior Bio, Inc. to develop a novel formulation of itraconazole.
• INTI has a premier Scientific Advisory Board consisting of five experienced Mohs surgeons.
• The company believes its current cash on hand is sufficient to execute its business plan without requiring additional clinical trials.

Negatives

• The company has a history of net losses, with a net loss of $3.3 million in 2024 and $3.0 million in 2023.
• INTI is a pre-revenue pharmaceutical development company and is thus subject to the risks associated with early-stage businesses in that industry.
• An active trading market for the company's common stock does not exist and may not develop or be sustained.
• The company acknowledges a significant deficiency in the number of personnel available to serve the Companys accounting function.

Risks

• The company's success depends on its ability to clinically develop and commercialize itraconazole or other product candidates.
• Clinical drug development involves a lengthy and expensive process with an uncertain outcome.
• The company faces substantial competition from other pharmaceutical and biotechnology companies.
• If the company is unable to obtain and maintain patent protection for its technology and products, its ability to commercialize its technology and products may be impaired.
• The company may be unable to raise sufficient capital on acceptable terms, or at all.

Future Outlook

The company expects to progress with the FDA in 2025 with a new formulation of itraconazole developed with Avior Bio, Inc., coupled with a crossover PK trial to show that their formulation of itraconazole delivers comparable levels of itraconazole as the SUBA Cap formulation used in prior clinical trials. The company believes its current cash is sufficient to execute its business plan without requiring additional clinical trials.

Management Comments

• Management believes that the company's current cash on hand is sufficient to continue to execute its business plan as currently anticipated, without another required clinical trial.
• Management believes that the company may not be able to adequately segregate responsibility over financial transaction processing and reporting.

Industry Context

The pharmaceutical industry is highly competitive, with rapid technological and regulatory changes, particularly in the oncology field. The company faces competition from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide.

Comparison to Industry Standards

• Genentech (Roche) was the first to achieve FDA approval for a Hedgehog pathway inhibitor with the development of vismodegib (Erivedge).
• Novartis introduced sonidegib (Odomzo), another Hedgehog pathway inhibitor approved for treating locally advanced BCCs in adult patients who are not candidates for surgery or radiation.
• PellePharm has developed topical patidegib, a Hedgehog pathway inhibitor designed to reduce BCC formation in BCCNS patients.
• Kintara Therapeutics has also made strides in BCCNS treatment with its REM-001 Therapy, which has received FDA Orphan Drug Designation.

Related Party Transactions

• The Company has engaged Avior Bio, Inc. (Avior), which is currently creating a novel formulation of itraconazole. Avior is a privately held drug development company whose President and Chairman of the Board, Niraj Vasisht, is a member of the Companys Board of Directors.

Stakeholder Impact

• The company's success will impact shareholders, employees, and patients with cancer and non-cancerous proliferation disorders.
• The company's ability to obtain regulatory approvals and commercialize its product candidates will affect its financial performance and the value of its common stock.

Next Steps

• Progress with the FDA to reach a conclusion on whether any additional clinical trials are required before submitting the New Drug Application (NDA).
• Continue to execute the business plan as currently anticipated, without another required clinical trial.
• Assess capital requirements for additional opportunities, at which time raising additional capital in the public market will be considered.

Key Dates

Keywords

itraconazole, cancer therapy, pharmaceutical development, BCCNS, prostate cancer, lung cancer, FDA, clinical trials, intellectual property, Avior Bio, licensing agreement, market opportunity